Skip to content
10-K

Annual Report

Ibere Pharmaceuticals

0001410578-22-000776

← back to feed
Filed
Mar 31, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow FY 2021 · Dec 31, 2021 −$868.75K
Operating Cash Flow FY 2021 · Dec 31, 2020 −$3.54K
Short Term Debt FY 2021 · Dec 31, 2021 $0
Cash And Equivalents FY 2021 · Dec 31, 2021 $458.39K
Cash And Equivalents FY 2021 · Dec 31, 2020 $175.37K
Stockholders Equity FY 2021 · Dec 31, 2021 −$10.85M
Stockholders Equity FY 2021 · Dec 31, 2020 $19.24K
Stockholders Equity FY 2021 · Oct 21, 2020 $0
Current Liabilities FY 2021 · Dec 31, 2021 $372.44K
Current Liabilities FY 2021 · Dec 31, 2020 $657.13K
Total Liabilities FY 2021 · Dec 31, 2021 $11.54M
Total Liabilities FY 2021 · Dec 31, 2020 $657.13K
Current Assets FY 2021 · Dec 31, 2021 $693.39K
Current Assets FY 2021 · Dec 31, 2020 $175.37K
Total Assets FY 2021 · Dec 31, 2021 $138.71M
Total Assets FY 2021 · Dec 31, 2020 $676.37K
Net Income FY 2021 · Dec 31, 2021 $1.56M
Net Income FY 2021 · Dec 31, 2020 −$5.76K
Operating Income FY 2021 · Dec 31, 2021 −$1M
Operating Income FY 2021 · Dec 31, 2020 −$5.76K